Contents
Key findings
- 1Two phase 3 randomised placebo-controlled trials in HIV-infected adults with abdominal fat accumulation showed ~15–18% reduction in visceral adipose tissue at 26 weeks; the effect reverses on stopping.
- 2Tesamorelin is the only GHRH analogue with an FDA approval; CJC-1295 and sermorelin share its mechanism but not its evidence.
- 3Off-label use for visceral fat in people without HIV rests on mechanism and small studies, not trials of comparable size.
- 4A phase 2 trial in HIV-associated NAFLD showed reduced liver fat; a small trial in older adults reported cognitive-test improvements. Both are preliminary.
- 5The label requires attention to glucose, IGF-1 monitoring, and contraindication with active malignancy — relevant to any long-term off-label use.
Evidence level
Established for its approved indication (two phase 3 RCTs, ~800 participants, ~15–18% visceral fat reduction at 26 weeks). Preliminary for liver fat in HIV, and for cognition in older adults; essentially untested at scale for visceral fat in people without HIV.
Regulatory status
FDA-approved (2010) for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. All other uses are off-label. Prohibited in sport under WADA S2.
Tesamorelin occupies a rare position: an approved growth-hormone-axis peptide with real phase 3 evidence — and, because of that, a favourite of clinics prescribing it far outside the population it was studied in. Both halves of that sentence are true. This analysis keeps them apart.
The question readers ask
Does tesamorelin reduce visceral fat, and does it work for me? For HIV-infected adults with lipodystrophy, yes — reliably, in phase 3 trials, while treatment continues. For everyone else, the answer is "probably by mechanism, but not demonstrated in trials of comparable size", and the fat returns on stopping.
What tesamorelin is
Tesamorelin is a 44-amino-acid analogue of growth hormone-releasing hormone (GHRH), stabilised against enzymatic breakdown. It stimulates the pituitary to release GH in its natural pulsatile pattern, raising IGF-1. It was developed by Theratechnologies and approved by the FDA in November 2010 as Egrifta.
The established evidence: HIV-associated lipodystrophy
Two phase 3 randomised, double-blind, placebo-controlled trials enrolled about 800 HIV-infected adults with abdominal fat accumulation. Visceral adipose tissue, measured by CT, fell about 15% over 26 weeks on tesamorelin versus a small increase on placebo[1]; the pooled analysis with a 52-week extension showed the reduction was maintained while treatment continued and lost when participants were switched to placebo[2]. Triglycerides improved modestly; glucose parameters needed monitoring.
Study details: Effects of tesamorelin, a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat — pooled analysis of two phase 3 trials with safety extension
- Study type
- rct
- Population
- HIV-infected adults with abdominal fat accumulation
- Sample size
- 806
- Primary result
- VAT −15.4% to −17.5% at 26 weeks; maintained to 52 weeks on drug; regained on placebo.
- Year
- 2010
- Source
- Journal of Clinical Endocrinology & Metabolism(link not yet independently re-verified)
That is established evidence for that indication: two adequately powered RCTs, consistent results, an FDA approval.
The off-label uses
Visceral fat in people without HIV. The mechanism does not depend on HIV, and it would be surprising if tesamorelin did nothing to visceral fat in other people with abdominal obesity. But "would be surprising" is not a trial. Studies in non-HIV populations are small and mostly investigate related outcomes; there is no phase 3 equivalent. Off-label prescribing for general body composition rests on extrapolation, and inherits the label's warnings and its central finding — the effect reverses on discontinuation.
Liver fat. A phase 2 randomised trial in 61 HIV-infected adults with non-alcoholic fatty liver disease found tesamorelin reduced liver fat and slowed fibrosis progression over 12 months[3]. Encouraging, small, and — again — in HIV.
Cognition. A randomised trial in 152 healthy older adults and adults with mild cognitive impairment reported that 20 weeks of tesamorelin improved a composite executive-function score compared with placebo[4]. It is a real controlled trial, and it is one trial with cognitive-test endpoints, unreplicated at scale, with no clinical dementia outcome. Grade: preliminary.
Study details: Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults — results of a controlled trial
- Study type
- Randomised, double-blind, placebo-controlled
- Population
- Healthy older adults and adults with MCI
- Sample size
- 152
- Primary result
- Tesamorelin improved a composite executive-function score vs placebo over 20 weeks.
- Limitations
- Small; cognitive-test endpoints; not replicated in a larger trial.
- Year
- 2012
- Source
- Archives of Neurology(link not yet independently re-verified)
Safety: what the label says, and why it matters off-label
Approved products come with labels, and tesamorelin's is informative[5]. Common adverse reactions include injection-site reactions, arthralgia, peripheral oedema, myalgia and paraesthesia. Glucose intolerance can occur and should be monitored. IGF-1 should be monitored and treatment reconsidered if persistently elevated. It is contraindicated with active malignancy, in pregnancy, and where the pituitary axis is disrupted. The label also notes that its long-term cardiovascular safety and the safety of chronic IGF-1 elevation have not been established.
For a 26-week course in the studied population, this is a manageable profile. For indefinite off-label use in otherwise healthy adults chasing body composition, every one of those points — glucose, IGF-1, malignancy, unknown long-term risk — is a live question with no trial to answer it.
Regulatory position
FDA-approved for one indication. Off-label prescribing is legal for licensed clinicians. Prohibited in sport under WADA S2. Compounded "tesamorelin" and grey-market products are not the approved drug.
Grades by claim
| Claim | Best evidence | Grade |
|---|---|---|
| Reduces visceral fat in HIV lipodystrophy | Two phase 3 RCTs, n≈800 | Established evidenceApproved indication |
| Reduces visceral fat in people without HIV | Mechanism; small studies | Preliminary evidenceExtrapolation |
| Reduces liver fat | Phase 2 RCT, n=61, HIV | Preliminary evidenceSmall RCT |
| Improves cognition | One RCT, n=152, test scores | Preliminary evidenceUnreplicated RCT |
| Benefit persists after stopping | Phase 3 extension: regain | Unsupported evidenceContradicted |
Where to go next
- Tesamorelin profile.
- CJC-1295 vs ipamorelin vs tesamorelin.
- CJC-1295 and ipamorelin: growth hormone research and unanswered risks.
Frequently asked questions
- What is tesamorelin approved for?
- Reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. That is the only FDA-approved indication.
- Does tesamorelin reduce belly fat in people without HIV?
- Its mechanism should apply, and small studies suggest an effect, but trials of comparable size to the HIV phase 3 programme have not been done. It is off-label, and the label notes visceral fat returns when treatment stops.
- Does tesamorelin improve memory?
- One randomised trial of 152 older adults reported improved executive-function scores over 20 weeks. It has not been replicated at scale, and it did not measure clinical outcomes like dementia.
- How is tesamorelin different from CJC-1295?
- Both are GHRH analogues, but tesamorelin completed phase 3 trials and is FDA-approved; CJC-1295 was abandoned in development and cannot lawfully be compounded.
References
Numbered in order of first use. Study type is shown for every source; see our methodology for how we rank evidence.
- 1.
Falutz J, Allas S, Blot K, et al.. Metabolic effects of a growth hormone-releasing factor in patients with HIV New England Journal of Medicine, 2007.
Randomized controlled trialHIV-infected adults with abdominal fat accumulationn = 412
Result: VAT −15.2% vs +5.0% placebo at 26 weeks.
Limitations: Effect reversed after discontinuation.
↑ back to text - 2.
Falutz J, Mamputu JC, Potvin D, et al.. Effects of tesamorelin, a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat — pooled analysis of two phase 3 trials with safety extension Journal of Clinical Endocrinology & Metabolism, 2010.
Randomized controlled trialHIV-infected adults with abdominal fat accumulationn = 806
Result: VAT −15.4% to −17.5% at 26 weeks; maintained to 52 weeks on drug; regained on placebo.
↑ back to text - 3.
Stanley TL, Fourman LT, Feldpausch MN, et al.. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV — a randomised, double-blind, multicentre trial The Lancet HIV, 2019.
Randomized controlled trialHIV-infected adults with NAFLDn = 61
Result: Hepatic fat fraction reduced (absolute −4.1% vs placebo) at 12 months; less fibrosis progression.
Limitations: Small; HIV population only.
↑ back to text - 4.
Baker LD, Barsness SM, Borson S, et al.. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults — results of a controlled trial Archives of Neurology, 2012.
Randomized controlled trialHealthy older adults and adults with MCIn = 152
Result: Tesamorelin improved a composite executive-function score vs placebo over 20 weeks.
Limitations: Small; cognitive-test endpoints; not replicated in a larger trial.
↑ back to text - 5.
Tesamorelin (Egrifta) prescribing information (DailyMed search) U.S. National Library of Medicine, DailyMed.
Regulatory source
Result: Indication, contraindications, warnings, IGF-1 monitoring, adverse reactions.
↑ back to text
Review status: Editorially reviewed against primary sources. This article was fact-checked against the primary sources listed in the references by our editorial team, and it has not been reviewed by a licensed clinician. It is educational content, not medical advice. Read our editorial policy and methodology. Spotted an error? Tell us.
